The International Journal of Neuropsychopharmacology
February 1, 2025
Martine Skumlien, Tom P. Freeman, Daniel L. Hall et al.
Abstract Background Cannabis, and its main psychoactive compound tetrahydrocannabinol (THC), may alter the brain’ s reward system both acutely and over time. The endocannabinoid and reward systems mature during adolescence and adolescents may therefore respond differently to acute cannabis exposure compared with adults. Despite this, no previous functional magnetic resonance imaging (fMRI)...
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
February 1, 2025
Costanza Mazzantini, Lorenzo Curti, Daniele Lana et al.
Cannabis derivatives are among the most widely used psychoactive substances in the world, which leads to growing medical concerns regarding its chronic use and abuse especially among adolescents. Exposure to THC during formative years produces long-term behavioral alterations that share similarities with symptoms of psychiatric and neurodevelopmental disorders. In this study, we have analyzed...
Neuropsychopharmacology
December 1, 2024
Charalampos Brakatselos, Alexia Polissidis, George Ntoulas et al.
10 citations
Repeated administration of ketamine (KET) has been used to model schizophrenia-like symptomatology in rodents, but the psychotomimetic neurobiological and neuroanatomical underpinnings remain elusive. In parallel, the unmet need for a better treatment of schizophrenia requires the development of novel therapeutic strategies. Cannabidiol (CBD), a major non-addictive phytocannabinoid has been...
Journal of Psychopharmacology
November 1, 2024
Yi-Chun Chang, Renee E Magnan, Michael J Cleveland et al.
2 citations
Limited research considers the quantity and potency of cannabis products along with social context on the subjective effects of real-world cannabis use. This study examined the subjective effects of acute use as a function of Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) doses and social context during cannabis use episodes. Ninety-six participants (43.75% male, Mage = 35.73) reporting...
Clinical Pharmacology & Therapeutics
November 1, 2024
Andriy A Gorbenko, Jules A A C Heuberger, Linda E. Klumpers et al.
17 citations
Cannabidiol (CBD), the main non-intoxicating compound in cannabis, has been hypothesized to reduce the adverse effects of Δ9-tetrahydrocannabinol (THC), the main psychoactive and analgesic component of cannabis. This clinical trial investigated the hypothesis that CBD counteracts the adverse effects of THC and thereby potentially improves the tolerability of cannabis as an analgesic. A...
European Neuropsychopharmacology
May 2024
Brooke Manning, Amie C Hayley, Sarah J Catchlove et al.
As cannabinoid-based medications gain popularity in the treatment of refractory medical conditions, it is crucial to examine the neurocognitive effects of commonly prescribed products to ensure associated safety profiles. The present study aims to investigate the acute effects of a standard 1 mL sublingual dose of CannEpil®, a medicinal cannabis oil containing 100 mg cannabidiol (CBD) and 5 mg...
Frontiers in Psychiatry
April 23, 2024
Kennadi Johnson, A. Weldon, Melissa A. Burmeister
Schizophrenia is a serious mental health disorder that confers one of the highest mortality rates of all psychiatric illnesses. Although the disorder’s psychotic symptoms are treatable with conventional antipsychotics, they remain incurable. Moreover, medication adherence is poor, and individuals with schizophrenia choose to self-medicate with illicit substances, including cannabis. It is...
Cannabis and Cannabinoid Research
April 2024
Mohammed A Mustafa, Justin L. Poklis, Kimberly N Karin et al.
Introduction: Cannabidiol (CBD) has gained considerable public and scientific attention because of its known and potential medicinal properties, as well as its commercial success in a wide range of products. Although CBD lacks cannabimimetic intoxicating side effects in humans and fails to substitute for cannabinoid type-1 receptor (CB1R) agonists in laboratory animal models of drug...
Neuroscience Letters
March 1, 2024
Guangzhao Shu, Yang He, Jin Suo et al.
Cannabidiol (CBD), a non-psychoactive compound derived from the cannabis plant, has been confirmed to induce anxiolytic-like and antipsychotic-like effects. However, the exact mechanisms remain unclear. This study substantiated CBD's interaction with the 5-HT1A receptor (5-HT1AR) in vitro (CHO cells expressing human 5-HT1AR) and in vivo (rat lower lip retraction test, LLR test). We then...
Psychopharmacology
February 28, 2024
Daniel L. Hall, Will Lawn, Shelan Ofori et al.
5 citations
RATIONALE: Attentional bias to drug-related stimuli is hypothesised to contribute towards addiction. However, the acute effects of Δ9-tetrahydrocannabinol (THC) on attentional bias to cannabis cues, the differential response in adults and adolescents, and the moderating effect of cannabidiol (CBD) are unknown. OBJECTIVES: Our study investigated (1) the acute effects of vaporised cannabis on...